Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported second quarter revenues of $3.16 billion, an 11% increase from one year earlier.
The company also reported the second quarter global net sales of Dupixent were $2.79 billion, a 33% year-over-year increase, and $1.5 billion in U.S. net sales of Eylea, a 7% decline from one year earlier. The company currently has approximately 35 product candidates in various stages of clinical development.
“Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth,” said Dr. Leonard S. Schleifer, board co-chairman, president and CEO of the Tarrytown-headquartered company. “In the past months, we have continued to advance our pipeline, in particular aflibercept 8 mg which we are progressing towards a potential FDA decision in the third quarter and for which we shared unprecedented two-year results in the pivotal Photon trial demonstrating durable vision gains at extended dosing intervals in patients with diabetic macular edema.”
“I am pleased with the performance of our business in the second quarter of 2023, including incremental pipeline progress and exceptional commercial execution,” added Robert E. Landry, executive vice president of finance and chief financial officer of Regeneron. “We continue to prioritize internal investments while allocating additional capital to opportunistic share repurchases and potential business development.”